<p>Perivascular adipose tissue (PVAT) influences the tone of vascular function through its endocrine, paracrine, and vasocrine functions. Obesity-induced PVAT inflammation promotes vascular dysfunction by shifting its secretory profile to a proinflammatory state. The intertwined nature of PVAT and vascular dysfunction in obesity calls for a drug that can target both simultaneously for effective mitigation of cardiovascular complications. Current therapeutic strategies target either systemic inflammation or vasoregulation, while a dual-targeting approach remains unexplored. Des-aspartate-angiotensin I (DAA-I) is a circulating angiotensin peptide with anti-inflammatory and vasoregulatory properties by modulating angiotensin receptor subtype 1 (AT1R). This review investigates DAA-I as a promising therapeutic agent that can target both PVAT inflammation and endothelial dysfunction simultaneously. It summarises the documented pharmacological potential of DAA-I, its impact on vascular function, and its potential implications for future clinical applications. Understanding its dual action could open an avenue for innovative therapeutic intervention in obesity-related cardiovascular diseases.</p> Graphical Abstract <p></p>